MBX Biosciences announces equity offering after stock doubles

MBX Biosciences

22/09/2025 21:34

** Shares of MBX Biosciences MBX.O down 3.8% in extended trading to $19.25 as it looks to capitalize on its surging stock by raising equity

    ** MBX shares on Mon closed up 100% at $20 after co said its experimental drug, canvuparatide, met main goal in mid-stage trial for adults with chronic hypoparathyroidism, a hormone disorder that causes low calcium levels

    ** After the bell, the Carmel, Indiana-based firm announces 10 million share offering

    ** JP Morgan, Jefferies, TD Cowen and Guggenheim are joint bookrunners

    ** Co went public last Sept after IPO of 10.2 mln shares priced at $16

    ** With ~33.6 mln shares outstanding, co has about $672 mln market cap

    ** All 7 analysts
    covering MBX are bullish with avg rating of 'strong buy"; median PT is $45, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))